MPR Weekly Dose

MPR Weekly Dose
  • 5.0 (3)
  • HEALTH & FITNESS
  • UPDATED BIWEEKLY

Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.

  1. MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review

    1D AGO

    MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review

    Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film formulation of sildenafil is approved; and the FDA accepts the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer.

    15 min
  2. MPR Weekly Dose Podcast #262 — Docs Turn to AAP's Vaccine Schedule; Safety Alert for Burn, Wound Products; SC Lecanemab to Be Reviewed; Cardamyst Nasal Spray Available; Gene Therapies Placed on Hold

    JAN 30

    MPR Weekly Dose Podcast #262 — Docs Turn to AAP's Vaccine Schedule; Safety Alert for Burn, Wound Products; SC Lecanemab to Be Reviewed; Cardamyst Nasal Spray Available; Gene Therapies Placed on Hold

    AAP maintains routine vaccine recs despite CDC changes; FDA warns of serious injury with wound and burn products; subcutaneous Alzheimer disease treatment under review; Cardamyst nasal spray available; and the FDA places clinical hold on 2 gene therapies.

    14 min
  3. MPR Weekly Dose Podcast #261 — New Research on Prenatal Acetaminophen Use; Chikungunya Vaccine Withdrawn; Nexplanon Use Extended; GLP-1 RAs and Suicidal Behavior; At-Home Device for Depression

    JAN 23

    MPR Weekly Dose Podcast #261 — New Research on Prenatal Acetaminophen Use; Chikungunya Vaccine Withdrawn; Nexplanon Use Extended; GLP-1 RAs and Suicidal Behavior; At-Home Device for Depression

    New research on acetaminophen use during pregnancy; the chikungunya vaccine Ixchiq is withdrawn; FDA approves Nexplanon for up to 5 years of use; suicidal ideation warning removed from GLP-1s; at-home neuromodulation therapy cleared for adults with major depressive disorder.

    14 min
  4. MPR Weekly Dose Podcast #260 — Top 2026 Health Trends With US News' Annika Urban

    JAN 16

    MPR Weekly Dose Podcast #260 — Top 2026 Health Trends With US News' Annika Urban

    Fifty-eight health experts have weighed in on the future of wellness. In this episode, we sit down with Annika Urban, health editor for US News and World Report, to analyze the implications of these findings. Annika shares her perspective on the major shifts happening across the health spectrum.

    12 min
  5. MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome

    12/12/2025

    MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome

    ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy approved for Wiskott-Aldrich syndrome.

    14 min
  6. MPR Weekly Dose Podcast #258 — Jaypirca Gains Expanded Approval; Allograft to Restore Nerve Function; Baxdrostat Gets Priority Review; Stargardt Tx Shows Promise; Edema Autoinjector Accepted for Review

    12/05/2025

    MPR Weekly Dose Podcast #258 — Jaypirca Gains Expanded Approval; Allograft to Restore Nerve Function; Baxdrostat Gets Priority Review; Stargardt Tx Shows Promise; Edema Autoinjector Accepted for Review

    Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that causes vision loss shows promise; and an autoinjector to treat edema is accepted for Priority Review.

    11 min
  7. MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval

    11/21/2025

    MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval

    Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo approved for HER2-mutant NSCLC.

    15 min
  8. MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen

    11/14/2025

    MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen

    The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen.

    14 min
See All (261)

Ratings & Reviews

5
out of 5
3 Ratings

About

Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.

Information

  • Creator
    MPR Weekly Dose
  • Years Active
    2020 - 2026
  • Episodes
    261
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    MPR Weekly Dose